

Elizabeth E Powell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4214/elizabeth-e-powell-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

11,115
citations

47
h-index

104
g-index

165
ext. papers

12,817
ext. citations

6.5
avg, IF

5.82
L-index

#	Paper	IF	Citations
151	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.. <i>Diabetic Medicine</i> , 2022 , e14799	3.5	2
150	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
149	The temporal pattern and lifestyle associations of respiratory virus infection in a cohort study spanning the first two years of life.. <i>BMC Pediatrics</i> , 2022 , 22, 166	2.6	0
148	Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2200083119	11.5	1
147	Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.. <i>BMC Health Services Research</i> , 2022 , 22, 487	2.9	0
146	Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis.. <i>Hepatology Communications</i> , 2022 ,	6	0
145	Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017. <i>Medicine (United States)</i> , 2022 , 101, e29217	1.8	0
144	Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. <i>Patient Preference and Adherence</i> , 2021 , 15, 2649-2658	2.4	0
143	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021 , 397, 2212-2224	40	145
142	Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. <i>EClinicalMedicine</i> , 2021 , 36, 100919	11.3	2
141	Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 873-884	4	8
140	Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. <i>Internal Medicine Journal</i> , 2021 , 51, 691-698	1.6	4
139	The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. <i>Hepatology Communications</i> , 2021 , 5, 891-905	6	1
138	Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. <i>BMJ Open Gastroenterology</i> , 2021 , 8,	3.9	4
137	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021 , 11, 2858	4.9	3
136	Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study. <i>BMJ Open Gastroenterology</i> , 2021 , 8,	3.9	1
135	Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. <i>Hepatology Communications</i> , 2020 , 4, 518-526	6	6

134	Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. <i>International Journal for Equity in Health</i> , 2020 , 19, 27	4.6	5
133	ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	7
132	Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. <i>Internal Medicine Journal</i> , 2020 , 50, 1142-1146	1.6	2
131	Nonalcoholic fatty liver disease burden: Australia, 2019-2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1628-1635	4	21
130	Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. <i>Hepatology Communications</i> , 2020 , 4, 1279-1292	6	6
129	Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCAL assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD). <i>BMC Health Services Research</i> , 2020 , 20, 335	2.9	1
128	Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC). <i>Patient Preference and Adherence</i> , 2020 , 14, 599-611	2.4	10
127	Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. <i>British Journal of Pharmacology</i> , 2019 , 176, 3775-3790	8.6	13
126	Engaging primary care clinicians in the assessment of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 458-460	24.2	2
125	Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	42
124	Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. <i>EClinicalMedicine</i> , 2019 , 11, 44-53	11.3	18
123	Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. <i>Hepatology Communications</i> , 2019 , 3, 620-631	6	20
122	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β dependent mechanisms. <i>Scientific Reports</i> , 2019 , 9, 1439	4.9	6
121	Weight-based tacrolimus trough concentrations post liver transplant. <i>Internal Medicine Journal</i> , 2019 , 49, 79-83	1.6	2
120	Contemporary Educational Interventions for General Practitioners (GPs) in Primary Care Settings in Australia: A Systematic Literature Review. <i>Frontiers in Public Health</i> , 2019 , 7, 176	6	3
119	Reply. <i>Hepatology Communications</i> , 2019 , 3, 1283-1284	6	
118	Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. <i>Frontiers in Immunology</i> , 2019 , 10, 293	8.4	59
117	Haemochromatosis: a clinical update for the practising physician. <i>Internal Medicine Journal</i> , 2018 , 48, 509-516	1.6	17

116	Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. <i>Internal Medicine Journal</i> , 2018 , 48, 144-151	1.6	53
115	Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 80-94	12.7	18
114	Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. <i>JCI Insight</i> , 2018 , 3,	9.9	21
113	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018 , 2, 893-905	6	32
112	Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 799-804	3.2	5
111	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , 2017 , 47, 429-435	1.6	13
110	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
109	Identifying areas of need relative to liver disease: geographic clustering within a health service district. <i>Australian Health Review</i> , 2017 , 41, 407-418	1.8	2
108	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
107	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 339	2.8	10
106	Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management. <i>Internal Medicine Journal</i> , 2017 , 47, 952-955	1.6	14
105	Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. <i>Medicine (United States)</i> , 2017 , 96, e6761	1.8	23
104	The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair. <i>Seminars in Cell and Developmental Biology</i> , 2017 , 61, 22-30	7.5	27
103	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017 , 2017, 7927685	2.8	10
102	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7321-7331	5.6	15
101	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016 , 7, 12757	17.4	73
100	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. <i>BMC Gastroenterology</i> , 2016 , 16, 114	3	20
99	The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. <i>Liver International</i> , 2016 , 36, 370-7	7.9	32

98	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
97	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
96	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. <i>American Journal of Pathology</i> , 2016 , 186, 524-38	5.8	18
95	CR1g-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. <i>JCI Insight</i> , 2016 , 1, e86914	9.9	32
94	Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation. <i>PLoS ONE</i> , 2016 , 11, e0157771	3.7	23
93	Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. <i>PLoS ONE</i> , 2016 , 11, e0167001	3.7	22
92	Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 68-77	6.1	6
91	Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease. <i>Internal Medicine Journal</i> , 2016 , 46, 420-6	1.6	7
90	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 210-22	3.8	48
89	Interferon- γ s12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
88	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. <i>BMJ Open</i> , 2015 , 5, e007451	3	42
87	Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. <i>Fibrogenesis and Tissue Repair</i> , 2015 , 8, 19		22
86	ELF score ≥ 8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. <i>Liver International</i> , 2015 , 35, 1673-81	7.9	43
85	Response to ELF cut-off points: aetiology is also a relevant factor. <i>Liver International</i> , 2015 , 35, 1921	7.9	
84	Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection. <i>PLoS ONE</i> , 2015 , 10, e0120642	3.7	25
83	New Paradigms in the Histopathology of NAFLD. <i>Current Hepatology Reports</i> , 2014 , 13, 81-87	1	
82	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. <i>BMC Gastroenterology</i> , 2014 , 14, 97	3	24
81	Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?. <i>Internal Medicine Journal</i> , 2014 , 44, 865-72	1.6	35

80	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014 , 59, 1393-405	11.2	235
79	Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17851-62	5.6	37
78	Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. <i>Liver International</i> , 2013 , 33, 569-79	7.9	35
77	CCR5- β 2 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. <i>Genes and Immunity</i> , 2013 , 14, 286-90	4.4	5
76	Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. <i>Internal Medicine Journal</i> , 2013 , 43, 247-53	1.6	45
75	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. <i>Liver International</i> , 2013 , 33, 624-32	7.9	40
74	BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. <i>Alcoholism: Clinical and Experimental Research</i> , 2013 , 37, 1771-8	3.7	6
73	Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention. <i>Internal Medicine Journal</i> , 2013 , 43, 1096-102	1.6	7
72	Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C. <i>Australian Health Review</i> , 2013 , 37, 218-22	1.8	11
71	Khat-associated hepatitis. <i>Medical Journal of Australia</i> , 2013 , 199, 498-9	4	9
70	Liver repercussions of defective gut surveillance. <i>Hepatology</i> , 2012 , 56, 1174-7	11.2	2
69	Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. <i>Gastroenterology</i> , 2012 , 143, 1244-1252.e12	13.3	111
68	Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?. <i>Australian Health Review</i> , 2012 , 36, 443-7	1.8	2
67	Macrophage secretory products induce an inflammatory phenotype in hepatocytes. <i>World Journal of Gastroenterology</i> , 2012 , 18, 1732-44	5.6	29
66	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. <i>Genome Medicine</i> , 2011 , 3, 57	14.4	57
65	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 319-27	4	14
64	Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. <i>Hepatology</i> , 2011 , 53, 1819-29	11.2	64
63	GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. <i>Endocrinology</i> , 2011 , 152, 181-92	4.8	118

62	Not every cell is as it seems: a role for ductular epithelial cells in fibrosis?. <i>Gut</i> , 2011 , 60, 1-2	19.2	1
61	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. <i>PLoS Medicine</i> , 2011 , 8, e1001092	11.6	93
60	Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. <i>Digestive Diseases</i> , 2010 , 28, 186-91	3.2	36
59	Kupffer cells and hepatocyte metabolism: a two-way street?. <i>Hepatology</i> , 2009 , 49, 690-2	11.2	3
58	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. <i>Nature Genetics</i> , 2009 , 41, 1100-4	36.3	1636
57	Combined approach for non-invasive measurement of liver pathology by MR. <i>Journal of Hepatology</i> , 2009 , 51, 1083-1084	13.4	1
56	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. <i>Journal of Hepatology</i> , 2009 , 51, 389-97	13.4	133
55	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. <i>Journal of Hepatology</i> , 2008 , 49, 1046-54	13.4	41
54	Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. <i>Molecular Diagnosis and Therapy</i> , 2008 , 12, 209-18	4.5	12
53	Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. <i>Journal of Magnetic Resonance Imaging</i> , 2008 , 28, 937-45	5.6	149
52	Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. <i>Hepatology</i> , 2008 , 48, 80-7	11.2	60
51	Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. <i>Gastroenterology</i> , 2007 , 133, 80-90	13.3	363
50	Obesity management in liver clinics: translation of research into clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 504-9	4	20
49	Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. <i>Clinics in Liver Disease</i> , 2007 , 11, 173-89, x	4.6	34
48	Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. <i>Gut</i> , 2006 , 55, 529-35	19.2	216
47	Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. <i>Gastroenterology</i> , 2006 , 130, 1636-42	13.3	449
46	Adiponectin and its receptors in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 43, 929-36	3.4	86
45	Steatosis is a cofactor in liver injury in hemochromatosis. <i>Gastroenterology</i> , 2005 , 129, 1937-43	13.3	129

44	Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. <i>Hepatology</i> , 2005 , 41, 809-18	11.2	284
43	Steatosis: co-factor in other liver diseases. <i>Hepatology</i> , 2005 , 42, 5-13	11.2	290
42	A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. <i>Journal of Medical Genetics</i> , 2005 , 42, e45	5.8	38
41	Nonalcoholic fatty liver disease: is all the fat bad?. <i>Internal Medicine Journal</i> , 2004 , 34, 187-91	1.6	27
40	CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. <i>Genes and Immunity</i> , 2004 , 5, 444-50	4.4	51
39	Chronic hepatitis C and steatosis. <i>Current Hepatitis Reports</i> , 2004 , 3, 123-128		18
38	Virus-specific CD8+ T lymphocytes within the normal human liver. <i>European Journal of Immunology</i> , 2004 , 34, 1526-31	6.1	29
37	Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. <i>Hepatology</i> , 2004 , 39, 1230-8	11.2	120
36	Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. <i>Liver Transplantation</i> , 2004 , 10, 397-403	4.5	4
35	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. <i>Gut</i> , 2004 , 53, 413-9	19.2	310
34	Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. <i>Psychosomatics</i> , 2004 , 45, 49-57	2.6	33
33	Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 386-92	4	62
32	Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. <i>Journal of Hepatology</i> , 2003 , 39, 967-71	13.4	77
31	In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. <i>Journal of Hepatology</i> , 2003 , 39, 1042-8	13.4	145
30	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. <i>International Journal of Epidemiology</i> , 2003 , 32, 717-24	7.8	110
29	Interaction of non-alcoholic fatty liver disease with other liver diseases. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2002 , 16, 767-81	2.5	41
28	Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. <i>Gut</i> , 2002 , 51, 89-94	19.2	204
27	Lymphocyte apoptosis and cell replacement in human liver allografts. <i>Transplantation</i> , 2002 , 73, 1828-34	4.8	14

26	Intensive dietary intervention improves weight maintenance in the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2002 , 36, 256	13.4	2
25	Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 255-63	4.5	28
24	Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. <i>Gastroenterology</i> , 2001 , 121, 148-55	13.3	244
23	Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. <i>Journal of Hepatology</i> , 2001 , 34, 314-20	13.4	120
22	Host genetic factors influence disease progression in chronic hepatitis C. <i>Hepatology</i> , 2000 , 31, 828-33	11.2	340
21	Detection of male DNA in the liver of female patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000 , 33, 690-5	13.4	70
20	Expression of cytokines and factors modulating apoptosis by human sinusoidal leucocytes. <i>Journal of Hepatology</i> , 2000 , 32, 392-8	13.4	16
19	Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 419-22	4	34
18	Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 801-3	4	23
17	Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. <i>Hepatology</i> , 1999 , 29, 1215-9	11.2	559
16	Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. <i>Hepatology</i> , 1999 , 30, 526-30	11.2	354
15	Role of donor leukocyte chimerism in establishing the etiology of neutropenia after liver transplantation. <i>Transplantation</i> , 1999 , 67, 1358-61	1.8	6
14	Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection. <i>Clinical Immunology and Immunopathology</i> , 1997 , 84, 139-44		13
13	Peripheral blood chimerism following human liver transplantation. <i>Hepatology</i> , 1997 , 25, 1233-6	11.2	50
12	Detection of circulating donor deoxyribonucleic acid by microsatellite analysis in a liver transplant recipient. <i>Liver Transplantation</i> , 1996 , 2, 391-4		15
11	Successful in vitro fertilization and pregnancy in a patient with autoimmune chronic active hepatitis and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995 , 10, 233-5	4	9
10	Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. <i>Journal of Clinical Investigation</i> , 1994 , 93, 2168-74	15.9	72
9	Liver, lipoproteins and disease: I. Biochemistry of lipoprotein metabolism. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992 , 7, 214-24	4	8

8	Liver, lipoproteins and disease: II. Clinical relevance of disordered cholesterol metabolism in liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992 , 7, 225-31	4	5
7	Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis. <i>Hepatology</i> , 1991 , 13, 455-459	11.2	48
6	Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis 1991 , 13, 455		9
5	Improvement in chronic hepatocerebral degeneration following liver transplantation. <i>Gastroenterology</i> , 1990 , 98, 1079-82	13.3	77
4	The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. <i>Hepatology</i> , 1990 , 11, 74-80	11.2	1172
3	Steatohepatitis associated with limb lipodystrophy. <i>Gastroenterology</i> , 1989 , 97, 1022-4	13.3	61
2	Does NASH or NAFLD Contribute to Comorbidity of Other Liver Diseases?276-288		
1	The Impact of Social Workers in Cirrhosis Care: a Systematic Review. <i>Current Treatment Options in Gastroenterology</i> ,1	2.5	0